Navigation Links
Experts from Penn's School of Medicine to present at ACC Annual Scientific Session
Date:3/30/2008

Penn experts will present research findings that could come to define new standards of cardiovascular diagnostics and care at this weekends conference of the American College of Cardiology, the foremost professional society representing heart specialists throughout the world. These experts will gather beginning this weekend in Chicago to present and discuss the latest advances in cardiovascular medicine, science and education.

To arrange interviews with any of these presenters or other Penn physicians who will be in attendance, please call 215-200-2313, or email holly.auer@uphs.upenn.edu. All research results are embargoed until the time they are presented during the conference.

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients with Coronary Heart Disease or Risk Equivalent

Emile R. Mohler, MD, Director of Vascular Medicine and Associate Professor of Medicine
10 a.m., Sunday, March 30

Dr. Mohler will present results of a trial that may herald a new class of medications to prevent heart attack and stroke. Researchers at Penn and several other sites around the world studied the safety and efficacy of the drug darapladib (manufactured by GlaxoSmithKline) on Lp-PLA, an enzyme associated with inflammatory activity and increased risk for heart attack and stroke.

The drug was tested among patients already taking a cholesterol-lowering statin drug. After 12 weeks on a daily regimen of 160 mg of darapladib, blood tests revealed a decrease in two important circulating biomarkers, suggesting a possible reduction in systemic inflammatory burden.

While the drug doesnt necessarily act to shrink plaque, Mohler says the research suggests that darapladib may reduce plaque inflammation and therefore lower rates of clot formation and heart attacks among patients with coronary heart disease.

These findings will be published in an upcoming issue of JACC, the Journal of the American College of Cardiology.


Under-Referral of Women for Atrial Fibrillation Ablation: Can This Be Explained by Gender Differences in Outcome?

Andrea M. Russo, MD, Electrophysiology Laboratory Director and Clinical Associate Professor of Medicine
10 a.m., Sunday, March 30

Dr. Russo and her colleagues from the division of cardiovascular medicine at Penn will present research on disparities in treatment of women suffering atrial fibrillation, one of the most common abnormal heart rhythms.

Although women represent more than half of patients with this serious rhythm problem, they are less likely to be referred for atrial fibrillation ablation a therapy that uses radiofrequency energy to cauterize the heart tissue around each pulmonary vein to keep abnormal electrical signals from reaching the rest of the heart and triggering the faulty rhythm than men.

Russo studied 1,165 women and men who underwent ablation at Penn and found that both groups had similar arrhythmia control at 24 months after the procedure (84 percent of women and 89 percent of men), suggesting that more women should be referred for ablation therapy.


Women Face Higher Risk for Decline in Left Ventricular Ejection Fraction Following Orthotopic Liver Transplant

James N. Kirkpatrick, MD, Assistant Professor of Medicine
10 a.m., Tuesday, April 1

Chronic liver disease patients often have low systemic vascular resistance that causes low blood pressure before liver transplant, but after receiving a new liver, they may suffer post-operative heart problems that leave the left ventricle unable to pump out an adequate amount of blood. This situation puts patients at a greater risk of organ failure and death.

Dr. Kirkpatrick and his colleagues studied 80 patients who received an orthotopic liver transplant the procedure in which the patients native liver is removed and replaced with a donor organ in the same spot to determine who would be more likely to suffer post-transplant complications of the left ventricle.

Researchers found that female patients were more likely to exhibit a left ventricular ejection fraction depression following transplant, with 36.7 percent of women suffering the complication, compared to 16 percent of men.

Kirkpatrick believes that careful pre-operative ventricular assessment may help identify patients who could benefit from careful monitoring of blood pressure, heart rate and volume status, and, possibly, serial echocardiograms. Some of these patients may benefit from aggressive treatment with medications like ACE-inhibitors and beta blockers. The Penn researchers plan to test newer echocardiographic techniques before and after transplant to refine ways to identify these patients.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Infant formula must contain DHA omega-3 and AA omega-6, say international experts
2. Teen Driving Experts at The Childrens Hospital of Philadelphia Support New Recommendations From the New Jersey Teen Driver Study Commission
3. NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports
4. ID, HIV experts urge more resources for TB
5. CMS Approves Home Sleep Testing for Diagnosis of OSA; AASM Experts Available for Comment
6. New England Area Fertility Experts Issue Call for Ethnic Egg Donors
7. Experts call for community mobilization to curb youth violence
8. The Chartis Group Elects New Partners: Four Healthcare Industry Experts Promoted to Principal
9. Experts will analyze the nutrition and health relationship from pregnancy to adolescence
10. Spiritual Health Experts Speak at Chaplains Conference in Pittsburgh March 8-12
11. Experts Delve Into Issues of HPV Vaccination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: